MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To guage multiple intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key trial goals had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis clients, while one of many exploratory https://franko887cny0.dm-blog.com/profile